This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis
- Generic Name
- Poliovirus type 2 antigen (formaldehyde inactivated)
- DrugBank Accession Number
- DB10796
- Background
Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Inactivated poliomyelitis vaccine (D.C.O.) type 2 MEF1
- Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
- Inactivated poliovirus type II
- Poliovirus vaccine inactivated, type 2 (MEF-1)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Poliomyelitis caused by poliovirus •••••••••••• Prevention of Poliomyelitis caused by poliovirus •••••••••••• Prevention of Poliomyelitis caused by poliovirus type 2 •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 23JE9KDF4R
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Acellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B 1 4 Completed Prevention Acellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus 1 4 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus 1 4 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B 1 4 Completed Prevention Acute Lymphoblastic Leukemia (ALL) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular Injection Intramuscular; Subcutaneous Solution Subcutaneous Injection, suspension Intramuscular; Subcutaneous Injection Suspension Intramuscular Injection, powder, for suspension Intramuscular Injection, suspension Intramuscular Injection; injection, suspension; kit Intramuscular Injection Intramuscular Injection, suspension Intramuscular 30 iu/0.5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:04 / Updated at November 28, 2021 16:22